Market Access Challenges and Solutions in Cell and Gene Therapy in The Netherlands
With the increasing pipeline of cell and gene therapies (CGTs) and the expected surge in the number of approvals, understanding the market access landscape becomes crucial for timely patient access. This study evaluates the challenges Dutch stakeholders encounter in CGT market access, offering insig...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-07-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2001-6689/12/3/15 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849396269315784704 |
|---|---|
| author | Rimma Velikanova Sharon Wolters Hinko S. Hofstra Maarten J. Postma Cornelis Boersma |
| author_facet | Rimma Velikanova Sharon Wolters Hinko S. Hofstra Maarten J. Postma Cornelis Boersma |
| author_sort | Rimma Velikanova |
| collection | DOAJ |
| description | With the increasing pipeline of cell and gene therapies (CGTs) and the expected surge in the number of approvals, understanding the market access landscape becomes crucial for timely patient access. This study evaluates the challenges Dutch stakeholders encounter in CGT market access, offering insights for improving time-to-patient access. A traditional literature review was conducted to identify market access challenges and solutions for CGTs. Based on the findings, participants for semi-structured interviews, designed using an interview guide adapted to the Dutch context, were selected to capture diverse perspectives on market access. This review included 124 relevant articles out of 2449, covering several aspects of market access of CGTs. Subsequently, interviews with 16 stakeholders from academia, patient advocacy groups, manufacturers, health insurers, payers, hospital pharmacists, healthcare practitioners, and the Association of Innovative Medicines were conducted. Stakeholders identified challenges and proposed solutions for reimbursement package management, clinical trials, health economics, payment models, and procedural and organisational aspects. Thematic analysis revealed unique country-specific challenges and solutions in the Netherlands. This research provides insights into these challenges and potential solutions, emphasising the need for collaborative efforts among stakeholders to develop practical and multidisciplinary measures to improve the market access landscape for CGTs in the country. |
| format | Article |
| id | doaj-art-b519cc560e7340159b2d030e294a05c0 |
| institution | Kabale University |
| issn | 2001-6689 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Market Access & Health Policy |
| spelling | doaj-art-b519cc560e7340159b2d030e294a05c02025-08-20T03:39:22ZengMDPI AGJournal of Market Access & Health Policy2001-66892024-07-0112318119810.3390/jmahp12030015Market Access Challenges and Solutions in Cell and Gene Therapy in The NetherlandsRimma Velikanova0Sharon Wolters1Hinko S. Hofstra2Maarten J. Postma3Cornelis Boersma4Department of Health Sciences, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsDepartment of Health Sciences, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsAsc Academics, Hereweg 120, 9725 AK Groningen, The NetherlandsDepartment of Health Sciences, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsDepartment of Health Sciences, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsWith the increasing pipeline of cell and gene therapies (CGTs) and the expected surge in the number of approvals, understanding the market access landscape becomes crucial for timely patient access. This study evaluates the challenges Dutch stakeholders encounter in CGT market access, offering insights for improving time-to-patient access. A traditional literature review was conducted to identify market access challenges and solutions for CGTs. Based on the findings, participants for semi-structured interviews, designed using an interview guide adapted to the Dutch context, were selected to capture diverse perspectives on market access. This review included 124 relevant articles out of 2449, covering several aspects of market access of CGTs. Subsequently, interviews with 16 stakeholders from academia, patient advocacy groups, manufacturers, health insurers, payers, hospital pharmacists, healthcare practitioners, and the Association of Innovative Medicines were conducted. Stakeholders identified challenges and proposed solutions for reimbursement package management, clinical trials, health economics, payment models, and procedural and organisational aspects. Thematic analysis revealed unique country-specific challenges and solutions in the Netherlands. This research provides insights into these challenges and potential solutions, emphasising the need for collaborative efforts among stakeholders to develop practical and multidisciplinary measures to improve the market access landscape for CGTs in the country.https://www.mdpi.com/2001-6689/12/3/15cell and gene therapiesmarket accesstime-to-patient accesshealth technology assessment (HTA)pharmaceutical policy |
| spellingShingle | Rimma Velikanova Sharon Wolters Hinko S. Hofstra Maarten J. Postma Cornelis Boersma Market Access Challenges and Solutions in Cell and Gene Therapy in The Netherlands Journal of Market Access & Health Policy cell and gene therapies market access time-to-patient access health technology assessment (HTA) pharmaceutical policy |
| title | Market Access Challenges and Solutions in Cell and Gene Therapy in The Netherlands |
| title_full | Market Access Challenges and Solutions in Cell and Gene Therapy in The Netherlands |
| title_fullStr | Market Access Challenges and Solutions in Cell and Gene Therapy in The Netherlands |
| title_full_unstemmed | Market Access Challenges and Solutions in Cell and Gene Therapy in The Netherlands |
| title_short | Market Access Challenges and Solutions in Cell and Gene Therapy in The Netherlands |
| title_sort | market access challenges and solutions in cell and gene therapy in the netherlands |
| topic | cell and gene therapies market access time-to-patient access health technology assessment (HTA) pharmaceutical policy |
| url | https://www.mdpi.com/2001-6689/12/3/15 |
| work_keys_str_mv | AT rimmavelikanova marketaccesschallengesandsolutionsincellandgenetherapyinthenetherlands AT sharonwolters marketaccesschallengesandsolutionsincellandgenetherapyinthenetherlands AT hinkoshofstra marketaccesschallengesandsolutionsincellandgenetherapyinthenetherlands AT maartenjpostma marketaccesschallengesandsolutionsincellandgenetherapyinthenetherlands AT cornelisboersma marketaccesschallengesandsolutionsincellandgenetherapyinthenetherlands |